Breaking News Instant updates and real-time market news.

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

, PSDO

Presidio

$16.56

-0.02 (-0.12%)

17:44
11/14/19
11/14
17:44
11/14/19
17:44

Paulson adds Callon Petroleum, lowers stake in Lyft in Q3

John Paulson's Paulson & Co. disclosed in an SEC filing its holdings as of September 30, 2019. Paulson's four new buys during the third quarter included, by size of position, Callon Petroleum (CPE), Presidio (PSDO), and Overseas Shipholding Group (OSG). The firm exited nine positions during the quarter, including Stewart Information (STC). Paulson increased its stake in eight holdings, including by size of previous position Allergan (AGN), Horizon Therapeutics (HZNP), Spark Therapeutics (ONCE), Mylan (MYL), and Sprint (S). The firm reduced its stake in nine holdings, including by size of previous position Lyft (LYFT), T-Mobile (TMUS), PG&E (PCG), WellCare Health Plans (WCG), and Tim Participacoes (TSU). Paulson's top holdings as of September 30, in order of size, were SPDR Gold Shares (GLD), Allergan, Bausch Health (BHC), Celgene (CELG), and Discovery Class C (DISCK).

CPE

Callon Petroleum

$4.20

-0.265 (-5.94%)

PSDO

Presidio

$16.56

-0.02 (-0.12%)

OSG

Overseas Shipholding

$1.84

0.045 (2.51%)

STC

Stewart

$43.10

0.11 (0.26%)

AGN

Allergan

$182.47

0.91 (0.50%)

HZNP

Horizon Pharma

$29.82

-0.48 (-1.58%)

ONCE

Spark Therapeutics

$110.78

-0.65 (-0.58%)

MYL

Mylan

$17.26

-0.01 (-0.06%)

S

Sprint

$5.86

-0.21 (-3.46%)

LYFT

Lyft

$41.90

-1.39 (-3.21%)

TMUS

T-Mobile

$76.87

-1.15 (-1.47%)

PCG

PG&E

$6.70

-0.19 (-2.76%)

WCG

WellCare

$301.86

-2.56 (-0.84%)

TSU

Tim Participacoes

$15.53

0.44 (2.92%)

GLD

SPDR Gold Shares

$138.57

0.59 (0.43%)

BHC

Bausch Health

$27.77

0.38 (1.39%)

CELG

Celgene

$110.03

-0.42 (-0.38%)

DISCK

Discovery Inc.

$28.04

0.12 (0.43%)

  • 14

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 07

    Jan

  • 25

    Mar

  • 04

    Apr

CPE Callon Petroleum
$4.20

-0.265 (-5.94%)

08/12/19
KEYB
08/12/19
DOWNGRADE
KEYB
Sector Weight
Carrizo Oil & Gas downgraded to Sector Weight from Overweight at KeyBanc
KeyBanc analyst Leo Mariani downgraded Carrizo Oil & Gas (CRZO) to Sector Weight from Overweight without a price target. The analyst does not see another buyer emerging after Callon Petroleum (CPE) agreed to acquire Carrizo for a 25% premium.
07/16/19
MKMP
07/16/19
DOWNGRADE
Target $11
MKMP
Neutral
Carrizo Oil & Gas downgraded to Neutral from Buy at MKM Partners
MKM Partners analyst John Gerdes downgraded Carrizo Oil & Gas (CRZO) to Neutral and lowered his price target to $11 from $19 after its announced acquisition by Callon Petroleum (CPE) in an all-stock deal. The analyst notes that the shares now trade with less than 10% equity value upside and warrant a neutral stance. Gerdes also calls the deal "sensible" given the companies' complementary Delaware Basin assets and greater operational efficiencies.
07/16/19
IMPC
07/16/19
NO CHANGE
Target $11
IMPC
Outperform
Callon Petroleum price target lowered to $11 from $16 at Imperial Capital
Imperial Capital analyst Irene Haas lowered her price target for Callon Petroleum (CPE) to $11 from $16 to reflect her firm's reduced price deck for 2019. The analyst, however, supports the larger combined entity created by the company's acquisition of Carrizo Oil & Gas (CRZO). She sees more scope, scale, and geographic diversity from the new company and keeps an Outperform rating on Callon.
11/05/19
11/05/19
NO CHANGE

Glass Lewis says Carrizo deal 'out of step' with Callon strategy, Bloomberg says
Proxy advisory firm Glass Lewis recommends Callon Petroleum (CPE) shareholders vote against the company's proposed all-stock acquisition of Carrizo Oil & Gas (CRZO), calling the acquisition of Carrizo "decidedly out of step" with Callon's stated strategy of focusing purely in the Permian Basin, according to Bloomberg's Nick Lichtenberg.
PSDO Presidio
$16.56

-0.02 (-0.12%)

12/04/18
RHCO
12/04/18
INITIATION
RHCO
Buy
Presidio initiated with a Buy at SunTrust
12/04/18
12/04/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Activision Blizzard (ATVI) initiated with a Buy at Gabelli. 2. Kratos Defense (KTOS) initiated with an Outperform at Baird. 3. Capital Product (CPLP) initiated with a Buy at B. Riley FBR. 4. Veeva (VEEV) initiated with an Outperform at Leerink. 5. Presidio (PSDO) initiated with a Buy at SunTrust. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
12/04/18
RHCO
12/04/18
INITIATION
Target $17
RHCO
Buy
Presidio initiated with a Buy at SunTrust
SunTrust analyst Frank Atkins initiated Presidio with a Buy rating and a price target of $17, saying the company has "carved out a solid niche in the technology ecosystem" through "value-added-reselling" of software and hardware to mid-market clients. The analyst notes that the company is broadening its revenue mix and increasing the amount of recurring revenue with added potential of gaining larger client traction. Atkins expects these "positive trends" to result in revenue and margin upside driven by "solid trajectory in the fundamentals".
06/06/19
EVER
06/06/19
INITIATION
Target $15
EVER
In Line
Presidio started with an In Line at Evercore ISI
Evercore ISI transferred coverage of Presidio to Ken Talanian, who started shares an In Line rating and $15 price target, saying he thinks Presidio is well-positioned to address the faster growing middle-market segment of the US IT market and should benefit from secular tailwinds such as OEMs increasingly selling through the channel vs. direct, IT workloads shifting to the cloud, and heightened demand for security solutions. Although the stock's valuation remains compelling, the analyst says he thinks the company may need to demonstrate a few quarters of consistent execution vs. their long-term target model before sentiment shifts positive.
OSG Overseas Shipholding
$1.84

0.045 (2.51%)

STC Stewart
$43.10

0.11 (0.26%)

12/31/18
PIPR
12/31/18
NO CHANGE
PIPR
Piper favors Fidelity National, RE/MAX amid slowing home sales
Existing home sales remained in a weak trend at down 4% year-over-year in November versus down 3% in October and down 2% in Q3, Piper Jaffray analyst Jason Deleeuw tells investors in a research note. The analyst believes the key drivers continue to be tight home inventories and increased discretion by home buyers after years of steady home price gains have reduced affordability. He continues to expect home sales trends to post low- to mid-single-digit declines for 2019. In this environment, Deleeuw's favorite real estate names are Fidelity National Financial (FNF) and RE/MAX Holdings (RMAX) since both have "catalysts/business models not as sensitive to sales volume trends." Fidelity National is the analyst's favorite real estate name given the potential earnings accretion from the pending Stewart (STC) acquisition that he believes is not factored much into the share price. Deleeuw also favors RE/MAX citing its "steady and high return business model that can sustain growth in multiple housing environments." Agent count and agent fees rather than volume drive the bulk of the company's franchise model economics, says Deleeuw.
02/04/19
PIPR
02/04/19
NO CHANGE
PIPR
Fidelity National likely unaffected by blocked Stewart deal, says Piper Jaffray
Piper Jaffray analyst Jason Deleeuw expects shares of Fidelity National Financial (FNF) to trade lower today after the New York State Department of Financial Services provided written notice of its disapproval of the company's application to acquire control of Stewart (STC). The analyst thinks the combined company's market share is the concern for the NYDFS. Deleeuw, however, does not believe a lot of Stewart accretion was priced into Fidelity National's valuation. In addition, the analyst thinks Fidelity's business will likely unaffected by a blocked Stewart deal. We don't see any business risk to Fidelity if the deal is blocked, as its operations should be unaffected, Deleeuw tells investors in a research note. He points out that Fidelity National would pay a $50M break-up fee to Stewart if the deal falls through for regulatory purposes. The analyst believes the company has not heard from the Federal Trade Commission or the Texas state regulators regarding the deal. Shares of Fidelity National Financial are down 2% to $35.67 in early trading while Stewart is down 7% to $41.88.
AGN Allergan
$182.47

0.91 (0.50%)

09/30/19
WELS
09/30/19
NO CHANGE
Target $184
WELS
Outperform
Allergan price target raised to $184 from $176 at Wells Fargo
Wells Fargo analyst David Maris raised his price target for Allergan (AGN) to $184 from $176 as the company is in the process of being acquired by AbbVie (ABBV) and to account for the change in the latter's stock price from the proposed deal. Despite the FTC's second request, he does not believe there is a significant risk of the deal not being finalized given the little overlap there is between the companies. The analyst reiterates an Outperform rating on Allergan's shares as he likes standalone Allergan shares, and believes the current deal spread is attractive.
10/30/19
WELS
10/30/19
UPGRADE
Target $20
WELS
Outperform
Wells Fargo upgrades Revance to Outperform, boosts target to $20
Wells Fargo analyst Jacob Hughes upgraded Revance Therapeutics (RVNC) to Outperform from Market Perform with a price target of $20, up from $12.50. After meeting with management, the analyst likes the setup for shares. Revance has a commercial-focused CEO with a history of shareholder value creation in aesthetics and a "catalyst rich" 12 months, Hughes tells investors in a research note. He believes the stock has "significant upside potential" and likes the cash pay nature of aesthetics. The multi-billion neurotoxins market will continue to expand, and disruption from the Allergan (AGN), AbbVie (ABBV) merger will create opportunities for Revance to take share, contends Hughes.
10/24/19
SPHN
10/24/19
NO CHANGE
Target $95
SPHN
Overweight
Glaukos could benefit from Allergan's 'unfortunate' XEN hold, says Stephens
Stephens analyst Chris Cooley noted Allergan's (AGN) initiation earlier this week of a voluntary recall of affected lots of XEN 45 and precautionary temporary product hold. Though XEN usage is reserved for moderate to severe cases of POAG, the "unfortunate" temporary hold may create additional opportunities for Glaukos (GKOS) to train and convert glaucoma specialists to iStent inject, contends Cooley. The analyst, who said he remains confident in Glaukos' ability to achieve low-teens percentage MIGS growth in calendar 2020, keeps an Overweight rating on Glaukos shares.
09/26/19
SBSH
09/26/19
UPGRADE
Target $90
SBSH
Buy
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal
Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential of both Skyrizi and Rinvoq.
HZNP Horizon Pharma
$29.82

-0.48 (-1.58%)

09/11/19
GUGG
09/11/19
INITIATION
GUGG
Buy
Horizon Pharma initiated with a Buy at Guggenheim
Guggenheim analyst Dana Flanders initiated Horizon Pharma with a Buy rating and a $36 price target, calling the company his "Best Idea." The analyst has high confidence in the growth potential of Horizon's drugs Krystexxa and teprotumumab, and believes they will drive upside to margins over the next 3-5 years. Flanders also expects a "strong" tepro launch in Q1 of 2020.
11/08/19
CANT
11/08/19
NO CHANGE
Target $36
CANT
Overweight
Horizon Pharma price target raised to $36 from $32 at Cantor Fitzgerald
Cantor Fitzgerald analyst Louise Chen raised her price target for Horizon Pharma to $36 from $32 following the company's "beat and raise" for Q3. The analyst continues to expect upside to consensus estimates for the company's orphan and rheumatology business as well as teprotumumab and multiple expansion to drive the stock. She keeps an Overweight rating on the name.
09/26/19
BOFA
09/26/19
INITIATION
Target $34
BOFA
Buy
Horizon Pharma initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Jason Gerberry initiated Horizon Pharma with a Buy rating and a price target of $34. The analyst contends that the stock can generate multiple expansion from its tepro approval and favorable payer coverage for thyroid eye disease as well as from the continued execution of Krystexxa re-launch and the "read-across to tepro launch hurdles".
10/11/19
PIPR
10/11/19
NO CHANGE
Target $33
PIPR
Overweight
Piper Jaffray rheumatologist survey favorable for Horizon Pharma
Piper Jaffray analyst David Amsellem says his survey of 25 rheumatologists who are current users of Horizon Pharma's Krystexxa in patients with chronic refractory gout reinforced his view that the rheumatology community's view of the risk/benefit profile of the product "continues to evolve considerably, pointing to greater usage among existing Krystexxa users." The feedback also bodes well for usage of the product among practices that are relatively new to Krystexxa, Amsellem tells investors in a research note. He continues to believe that the combination of "continued aggressive" Krystexxa growth along with contribution from teprotumumab starting next year points to a longer term annual EBITDA growth for Horizon "at least in the high-teens." Amsellem keeps an Overweight rating on the shares with a $33 price target.
ONCE Spark Therapeutics
$110.78

-0.65 (-0.58%)

10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
06/11/19
JANY
06/11/19
NO CHANGE
JANY
Buy
uniQure weakness a buying opportunity, says Janney Montgomery Scott
Janney Montgomery Scott analyst Yun Zhong said he does not see any fundamental reason for today's weakness in shares of uniQure (QURE), attributing the pullback as likely due to profit taking following some recent strong performance. Roche's (RHHBY) deal to buy Spark Therapeutics (ONCE) in February had a positive impact on the overall gene therapy sector and investor speculation has contributed to an over 30% increase in uniQure shares over the past two weeks, noted Zhong, who said his valuation does not include any acquisition assumption or premium. The analyst, who sees uniQure having the first FDA approval for an AAV gene therapy for hemophilia B and the first AAV gene therapy program in the clinic for Huntington's disease, keeps a Buy rating on the stock and would be a buyer amid today's weakness.
05/28/19
FBCO
05/28/19
NO CHANGE
Target $133
FBCO
BioMarin data alleviates valrox durability overhang, re-awakens M&A, says Credit Suisse
Credit Suisse raised its price target for BioMarin (BMRN) to $133 from $131, while nudging up valrox Probability of Success to 75% from 65%. The firm thinks the valoctocogene roxaparvovec data largely alleviates the valrox durability overhang and re-awakens an M&A thesis on BioMarin on the value of its gene therapy platform. The company's de-risked Phase 3 valrox program and established mfg infrastructure put the company's gene tx assets in the valuation range up to that established by the AveXis (AVXS) and Spark Therapeutics (ONCE) transactions, Credit Suisse contends.
03/25/19
LEHM
03/25/19
DOWNGRADE
Target $115
LEHM
Equal Weight
Spark Therapeutics downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Gena Wang downgraded Spark Therapeutics to Equal Weight from Overweight while raising her price target for the shares to $115 from $74. The analyst cites the pending takeover by Roche (RHHBY) for the downgrade.
MYL Mylan
$17.26

-0.01 (-0.06%)

11/05/19
CFRA
11/05/19
DOWNGRADE
CFRA
Sell
Mylan downgraded to Sell from Hold at CFRA
CFRA downgraded Mylan to Sell from Hold.
11/07/19
MSCO
11/07/19
DOWNGRADE
Target $18
MSCO
Equal Weight
Mylan downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst David Risinger downgraded Mylan to Equal Weight from Overweight with an $18 price target.
11/07/19
11/07/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Twitter (TWTR) downgraded to Underperform from In Line at Evercore ISI with analyst Kevin Rippey citing his view that 2018 represented a period of "unsustainably high" margins as Twitter reaped the benefits of a period of sustained underinvestment. 2. Mylan (MYL) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst David Risinger sayinge has become more conservative in his estimates after competing U.S. generic businesses missed estimates in the past two days, which he thinks may be indicative of ongoing industry pressures. 3. Expedia (EXPE) downgraded to Neutral from Overweight at Piper Jaffray and to Neutral from Buy at DA Davidson and BofA/Merrill. 4. Bloomin' Brands (BLMN) downgraded to Neutral from Overweight at JPMorgan with analyst John Ivankoe citing valuation. 5. Papa John's (PZZA) downgraded to Neutral from Buy at MKM Partners with analyst Brett Levy saying the company has generated its first positive domestic comps in two years while laying the foundation for a "potential turnaround," but after a 43% run-up in the stock price since August 23, he believes the valuation warrants a neutral stance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/19
MSCO
11/07/19
DOWNGRADE
Target $18
MSCO
Equal Weight
Mylan downgraded to Equal Weight on growth uncertainty at Morgan Stanley
As previously reported, Morgan Stanley analyst David Risinger downgraded Mylan to Equal Weight from Overweight with a price target of $18, down from $25. He has become more conservative in his estimates after competing U.S. generic businesses missed estimates in the past two days, which he thinks may be indicative of ongoing industry pressures, Risinger tells investors. After management's Q3 call comments implied uncertainty about 2020 and beyond, and three other generic businesses reported disappointing results over the past two days, Risinger has cut his out-year forecasts for revenue and margins. His long-term EPS is now 6% below consensus for Mylan, the analyst noted.
S Sprint
$5.86

-0.21 (-3.46%)

11/04/19
RAJA
11/04/19
UPGRADE
Target $49
RAJA
Strong Buy
U.S. Cellular upgraded to Strong Buy from Outperform at Raymond James
Raymond James analyst Ric Prentiss upgraded U.S. Cellular to Strong Buy from Outperform with a price target of $49, down from $53, following what he calls an overreaction on Friday to the Q3 results. In a research note to investors, Prentiss says he believes the brand refresh and new rate plans will continue to drive foot traffic into stores, helping postpaid phone subscriber growth and continues to believe the best option to maximize return on invested capital for U.S. Cellular would be to affiliate with, or sell to, a larger carrier, whether the T-Mobile (TMUS)-Sprint (S) merger is approved or not. The analyst views shares as "very attractive."
11/01/19
COWN
11/01/19
NO CHANGE
Target $260
COWN
Outperform
American Tower price target raised to $260 from $238 at Cowen
Cowen analyst Colby Synesael raised his price target on American Tower (AMT) to $260 from $238 following in-line Q3 results. The analyst said the recent India situation as well as the pending T-Mobile (TMUS)/Sprint (S) merger creates near-term uncertainty but he views the recent selloff as a buying opportunity. He expects more meaningful upside in 2020 when the India and merger situations are resolved. Synesael maintained his Outperform rating on American Tower shares.
11/14/19
HSBC
11/14/19
DOWNGRADE
HSBC
HSBC downgrades AT&T, Verizon, T-Mobile and Altice USA to Hold
HSBC analyst Sunil Rajgopal downgraded to Hold from Buy shares of AT&T (T), Verizon Communications (VZ), T-Mobile (TMUS) and Altice USA (ATUS). The analyst's only Buy in US Telecoms is now Comcast (CMCSA). Rajgopal keeps Reduce ratings on both Dish (DISH) and Sprint (S). The "evolving content business model" and increasing competition leads the analyst to be more cautious on the pay-TV business and operators with greater exposure to content revenues. Producers are increasingly distributing their content directly to consumers rather than relying on the cable and satellite aggregators, Rajgopal tells investors in a research note. In addition, the entry of a "well-funded" companies like Apple (AAPL) into content production and distribution "with its low sticker price adds to the concerns," contends the analyst. Rajgopal cut his pay-TV subscriber estimates for Comcast, AT&T, Charter and Altice USA to reflect his more cautious stance. The analyst lowered his price target for Altice USA to $28 from $30, raised his price target for AT&T to $42 from $38, raised his price target for Verizon to $65 from $62, and kept an $86 price target on T-Mobile.
10/29/19
RHCO
10/29/19
NO CHANGE
Target $95
RHCO
Buy
T-Mobile price target raised to $95 from $80 at SunTrust
SunTrust analyst Greg Miller raised his price target on T-Mobile (TMUS) to $95 and kept his Buy rating, saying the company's Q3 results continue to "demonstrate strength" of its "UnCarrier strategy" and its ability to capture market share in a more "competitive and mature" market place. The analyst further states that he remains optimistic that the company's can close its Sprint (S) merger with only an approval by federal regulators and contends that T-Mobile remains among "best" in the space.
LYFT Lyft
$41.90

-1.39 (-3.21%)

10/31/19
10/31/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Lowe's (LOW) upgraded to Overweight from Equal Weight at Barclays with analyst Karen Short saying total comp expectations for Q3 may be too high due to the expected drag from Canada as well as ongoing weakness in e-commerce, but believe the U.S. comp estimate of 3.6% "is what matters and is more achievable." 2. Sony (SNE) upgraded to Buy from Neutral at UBS. 3. Ensign Group (ENSG) upgraded to Buy from Hold at Stifel with analyst Chad Vanacore saying he sees a potential real estate spin-off or sale on the horizon. 4. Lyft (LYFT) upgraded to Buy from Neutral at Goldman Sachs with analyst Heath Terry saying the company reported better than expected Q3 revenue and management noted a trend toward higher prices across the industry, incremental engagement per rider, and a less promotional competitive environment. 5. Brinker (EAT) upgraded to Overweight from Neutral at Piper Jaffray with analyst Nicole Miller Regan saygin the company's return to EBITDA growth should drive a re-rating of the multiple. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/19
BOFA
11/07/19
NO CHANGE
Target $44
BOFA
Buy
Uber trading at discount to peers amid lock-up pressure, says BofA/Merrill
BofA Merrill Lynch analyst Justin Post noted that 134M shares of Uber stock traded yesterday, which compares to average daily volume of about 12M shares since its IPO and represents around 9% of the 1.4B shares unlocked by the expiration of the IPO lock-up provisions. The stock's roughly 4% decline was consistent with the recent basket of Internet IPOs he compares it to, which declined 2.3% on average on the day of lock-up expiration, Post added. He thinks lock-up related selling will likely remain a headwind in November, but he also notes that the company's current adjusted market cap of $30.4B implies a valuation discount to GrubHub (GRUB) and Lyft (LYFT). The analyst, who sees support coming from new segment disclosures and sum-of-the-parts valuation despite the lock-up overhang, keeps a Buy rating on Uber shares with a $44 price target.
10/31/19
JPMS
10/31/19
NO CHANGE
Target $85
JPMS
Overweight
Lyft taking share in 'increasingly rational' market, says JPMorgan
Lyft continues to take share of an "increasingly rational" U.S. rideshare market, thereby accelerating its path to profitability, JPMorgan analyst Doug Anmuth tells investors in a post-earnings research note. While Lyft reiterated its expectation for consolidated EBITDA profit by Q4 of 2021, the analyst continues to believe core rideshare can be profitable "well before that," potentially sometime in 2020. The analyst lowered his price target for the shares to $85 from $90 and reiterates an Overweight rating on Lyft.
10/31/19
MKMP
10/31/19
NO CHANGE
Target $50
MKMP
Neutral
Lyft price target raised to $50 from $45 at MKM Partners
MKM Partners analyst Rohit Kulkarni raised his price target on Lyft to $50 but kept his Neutral rating after its Q3 results. The analyst notes that the company's key metrics, like the number of active riders and revenue per rider, trended higher on a sequential basis, but he prefers to remain on the sidelines until there is more clarity around the impact of regulations in New York and San Francisco.
TMUS T-Mobile
$76.87

-1.15 (-1.47%)

11/14/19
11/14/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Apple (AAPL) downgraded to Sell from Hold at Maxim with analyst Nehal Chokshi saying his survey data lead him to project iPhone revenue in fiscal Q2 that is 14% below consensus iPhone revenue that is 6% below consensus for fiscal year 2020. He also expects operating profit to decline year-over-year due to his below consensus iPhone view. 2. Kraft Heinz (KHC) downgraded to Sell from Neutral at Goldman Sachs with analyst Jason English saying shares are up 15% since the company reported Q3 results on October 31. 3. Verizon (VZ), AT&T (T), and T-Mobile (TMUS) downgraded to Hold from Buy at HSBC. 4. Myomo (MYO) downgraded to Neutral from Buy at Roth Capital with analyst Scott Henry saying he sees lowered future expectations for the company after its Q3 results missed expectations. 5. Albemarle (ALB) downgraded to Neutral from Buy at Seaport Global with analyst Michael Harrison saying "challenging" lithium market dynamics are now anticipated to continue though 2020. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
11/14/19
HSBC
11/14/19
DOWNGRADE
Target $86
HSBC
Hold
T-Mobile downgraded to Hold from Buy at HSBC
HSBC analyst Sunil Rajgopal downgraded T-Mobile to Hold from Buy with an $86 price target.
PCG PG&E
$6.70

-0.19 (-2.76%)

10/25/19
MSCO
10/25/19
NO CHANGE
Target $16
MSCO
Equal Weight
Morgan Stanley says report raises risk that PG&E equipment involved in fire
Morgan Stanley analyst Stephen Byrd said PG&E filed an incident report on Thursday evening about the Kincade Fire which contained details that, while not necessarily indicating that the utility's equipment caused the fire, raise the risk that PG&E equipment could have been involved. He has an Equal Weight rating and $16 price target on PG&E shares, which are down about 20% to $5.72 at time of writing, off their worst levels from earlier in the pre-market session.
10/28/19
WOLF
10/28/19
DOWNGRADE
Target $19
WOLF
Peer Perform
Clearway Energy downgraded to Peer Perform on PG&E risk at Wolfe Research
Wolfe Research analyst Steve Fleishman downgraded Clearway Energy (CWEN) to Peer Perform from Outperform with a price target of $19, down from $21. The analyst notes Clearway has the most exposure to PG&E (PCG) with 30% of consolidated CAFD derived from the company.
11/12/19
SBSH
11/12/19
NO CHANGE
Target $5
SBSH
Sell
PG&E may offer both cash and stock to to TCC, says Citi
Citi analyst Praful Mehta notes that PG&E looking to offer the Tort Claimants Committee $13.5B, as reported yesterday by Bloomberg, would be the same amount that the bondholders have offered. It may be possible that PG&E offers a combination of cash and stock to the TCC to limit the size of the rights offering, Mehta tells investors in a research note. The value at which these shares are issued will also be a question, adds the analyst. He believes PG&E's total equity raise would be $27B, assuming holdco debt financing capacity of $4B. The analyst assumes a pro forma stock price of $4.80 per share with rights at $3.90 per share. Mehta keeps a Sell rating on PG&E with a $5 price target.
10/25/19
SBSH
10/25/19
NO CHANGE
Target $5
SBSH
Sell
Kincade fire increases probability of PG&E shares going to zero, says Citi
As of this morning, the Kincade fire covered ten thousand acres, was not contained and caused damage to two structures, Citi analyst Praful Mehta tells investors in a research note. It is not clear if PG&E equipment was involved, says Mehta, who believes shareholders are worried "and should be." It is important to note that any damages from a 2019 fire may be treated as post-petition claims that could recover 100 cents on the dollar, Mehta points out. Per AB1054, the wildfire fund is only liable to pay 40% of the damages for a 2019 fire. Further, the analyst believes that if Kindcade causes significant damage, PG&E's claim estimation and financing plans are likely to get delayed. Given the already very tight schedule to hit the June 2020 timeline per AB1054, a significant fire puts a timely exit and AB1054 at risk, says Mehta. As a result, the analyst believes the Kincade fire increases the probability of a zero share price for PG&E. While the bondholder plan wipes out existing shareholders, a large 2019 wildfire liability will also result in a similar outcome "purely from the liabilities and the associated need for additional financing," Mehta argues. He keeps a Sell rating on PG&E shares with a $5 price target. The probability of a zero equity value continues to increase, he says.The stock in premarket trading is down 28%, or $2.04, to $5.16.
WCG WellCare
$301.86

-2.56 (-0.84%)

10/16/19
MSCO
10/16/19
NO CHANGE
Target $294
MSCO
Overweight
UnitedHealth comments on 2020 eased concerns about MCOs, says Morgan Stanley
Morgan Stanley analyst Ricky Goldwasser noted that concerns over democratic presidential candidates' positions on "Medicare For All" have been weighing on the Managed Care Organization group since April when a bill was officially introduced in congress by Bernie Sanders. However, UnitedHealth (UNH) shares rose sharply, and the MCO group joined in yesterday, after the company reported an in-line Q3 Medical Loss Ratio, or MLR, and gave commentary on 2020 that eased market concerns around fundamentals, Goldwasser said. The analyst, who keeps an Overweight rating on UnitedHealth with a $294 price target, said the next catalyst for the MCO group will be Anthem's (ANTM) earnings report on October 23. Other publicly traded companies in the healthcare insurance space include CVS Health (CVS), Centene (CNC), Cigna (CI), Health Net (HNT), Humana (HUM), Molina Healthcare (MOH) and WellCare (WCG).
10/01/19
SPHN
10/01/19
NO CHANGE
SPHN
Stephens lowers price targets for MCOs on 2020 election uncertainty
Stephens analyst Scott Fidel said the uncertainty over the 2020 elections has been a consistent overhang for Managed Care Organization stocks, but the group has underperformed the S&P 500 Index by about 15% since Elizabeth Warren's polling numbers for the Democratic presidential nomination rose above the 18% range in mid-August. Given the continuing uncertainty about the 2020 election, especially in light of Warren's rise and "the Ukraine imbroglio" adding new risks for both Trump and Biden, Fidel lowered his price targets across the MCO group. However, he maintains his ratings, noting that the group now trades at its largest discount to the S&P since February 2010. Fidel lowered his price target price on Anthem (ANTM) shares to $306 from $350, trimmed his Cigna (CI) target to $206 from $225, lowered his Centene (CNC) target to $60 from $72, cut his Humana (HUM) target to $307 from $335, lowered Magellan Health's (MGLN) target to $65 from $74, decreased his Molina Healthcare (MOH) target to $126 from $150, lowered UnitedHealth's (UNH) target to $258 from $290 and cut his target for WellCare (WCG) to $287 from $317.
10/10/19
JEFF
10/10/19
DOWNGRADE
Target $235
JEFF
Hold
Jefferies downgrades UnitedHealth to Hold, cuts Managed Care price targets
Jefferies analyst David Windley downgraded UnitedHealth (UNH) to Hold from Buy with a price target of $235, down from $300. Managed Care sentiment "turned abruptly negative a year ago and has stubbornly remained there," Windley tells investors in a research note. Further, the political risk causing this won't likely abate for at least another nine months, contends the analyst. In addition to the political overhang, he's concerned UnitedHealth's (UNH) commercial enrollment is at risk to Anthem (ANTM). Along with the downgrade of UnitedHealth, Windley cut his price target for Buy-rated Anthem to $299 from $365, for Buy-rated Centene (CNC) to $53 from $76, for Buy-rated Cigna (CI) to $203 from $233, for Buy-rated Humana (HUM) to $322 from $352, for Buy-rated Molina Healthcare (MOH) to $133 from $173 and for Hold-rated WellCare (WCG) to $264 from $302.
10/10/19
RHCO
10/10/19
NO CHANGE
Target $330
RHCO
Hold
SunTrust 'bullish' across healthcare services space ahead of Q3 results
SunTrust analyst David MacDonald says he remains "bullish" across much of the healthcare services space ahead of third quarter results, citing "solid" core trends, "attractive" secular tailwinds, "robust" M&A and "strong" free cash flow. While he expects ongoing intermittent "chop" as industry noise continues to weigh, he views the risk of meaningful structural change as quite low, continues to favor scaled, integrated providers in the ongoing shift towards value and views valuation risk/rewards as increasingly attractive. The analyst tells investors in a research note that he does not necessarily view Q3 results as a meaningful trigger and thinks improved visibility around the election and Democratic primary is key, MacDonald remains bullish on core fundamentals, sees significant inherent sector drivers and says Managed Care remains a favorite fundamental sector. The analyst raised his price target for Anthem (ANTM) to $330 from $290, on Centene (CNC) to $80 from $72, on Cigna (CI) to $260 from $230, on Humana (HUM) to $340 from $310, on Molina (MOH) to $180 from $165, on UnitedHealth (UNH) to $330 from $310, on WellCare (WCG) to $340 from $320, on Ensign Group (ENSG) to $60 from $44 and Tivity Health (TVTY) to $24 from $21.
TSU Tim Participacoes
$15.53

0.44 (2.92%)

08/01/19
LEHM
08/01/19
UPGRADE
Target $19
LEHM
Overweight
Tim Participacoes upgraded to Overweight from Equal Weight at Barclays
Barclays analyst Mathieu Robilliard upgraded Tim Participacoes to Overweight from Equal Weight and raised his price target for the shares to $19 from $17.
08/01/19
LEHM
08/01/19
NO CHANGE
LEHM
Barclays upgrades Tim Participacoes to Overweight, downgrades Telefonica Brasil
Barclays analyst Mathieu Robilliard upgraded Tim Participacoes (TSU) to Overweight from Equal Weight with a price target of $19 while downgrading Telefonica Brasil (VIV) to Equal Weight from Overweight with a price target of $14. After a trip to Brazil, the analyst is more positive on mobile and more cautious on fixed. In mobile, prepaid makes for a high sensitivity to the macro, where prospects are improving with reform momentum, Robilliard tells investors in a research note. However, in fixed, the analyst sees a "structural increase in competition driven by new players." In addition, the timing of the approval of telecom reform remains uncertain, says Robilliard.
06/20/19
NWST
06/20/19
UPGRADE
NWST
Buy
Tim Participacoes upgraded to Buy from Neutral at New Street
06/05/19
MSCO
06/05/19
DOWNGRADE
Target $16
MSCO
Equal Weight
Tim Participacoes downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Cesar Medina downgraded Tim Participacoes to Equal Weight from Overweight and lowered his price target for the shares to $16 from $19.
GLD SPDR Gold Shares
$138.57

0.59 (0.43%)

BHC Bausch Health
$27.77

0.38 (1.39%)

11/05/19
LEHM
11/05/19
NO CHANGE
Target $30
LEHM
Overweight
Bausch Health price target raised to $30 from $28 at Barclays
Barclays analyst Balaji Prasad raised his price target for Bausch Health Companies to $30 from $28 and keeps an Overweight rating on the shares. The company's Q3 results "came in strong," as Bausch continued to drive organic growth on the back of Xifaxan growth of 24%, and management again raised 2019 revenue and adjusted EBITDA guidance, Prasad tells investors in a post-earnings research note. He expects multiple expansion in the shares.
10/03/19
PIPR
10/03/19
NO CHANGE
Target $29
PIPR
Overweight
Bausch unlikely to face generic Xifaxan before 2028, says Piper Jaffray
Piper Jaffray analyst David Amsellem says he would not be worried that a generic Xifaxan entrant will emerge prior to the January 2028 launch date outlined in Bausch Health Companies' (BHC) settlement with Teva (TEVA) on its generic filing. The analyst highlights the "relatively complex nature" of Xifaxan and Bausch's "fairly deep intellectual property estate." As such, he continues to believe that visibility into a "durable" EBITDA for Bausch Health is high, with a longer-term annual growth "reaching at least the high single digits." He reiterates an Overweight rating on the shares with a $29 price target.
10/25/19
COWN
10/25/19
INITIATION
Target $35
COWN
Outperform
Bausch Health initiated with an Outperform at Cowen
Cowen analyst Ken Cacciatore initiated coverage of Bausch Health with an Outperform rating as he believes management has successfully transformed and is slowly strengthening its portfolio. The company is also launching new products across the key B&L, Salix, and Dermatological segments while growing its Xifaxan franchise. Cacciatore has a $35 price target on Bausch Health shares.
09/17/19
WELS
09/17/19
NO CHANGE
WELS
Underperform
Wells says two of Bausch's 'Significant Seven' not on UnitedHealth benefit list
Wells Fargo analyst David Maris noted that United Healthcare (UNH) released its Pharmacy Benefit Coverage update, which shows that as of January 2020 it is excluding Bausch Health's (BHC) Bryhali, which he said is one of the company's "Significant Seven" focus products. Another of the Significant Seven, Siliq, will no longer be covered under UnitedHealth's pharmacy benefit plans, said Maris. Two other Significant Seven members - Vyzulta and Relistor - are listed as required step therapy and needing a prior authorization, respectively, Maris added. The analyst, who thinks Bausch Health's pipeline and recently approved products are "unimpressive," keeps an Underperform rating on the stock. Reference Link
CELG Celgene
$110.03

-0.42 (-0.38%)

09/23/19
GUGG
09/23/19
UPGRADE
Target $55
GUGG
Buy
Agios Pharmaceuticals upgraded to Buy following selloff at Guggenheim
Guggenheim analyst Michael Schmidt upgraded Agios Pharmaceuticals (AGIO) to Buy from Neutral following a 20% year-to-date selloff in the shares, stating that the current valuation reflects no value beyond Tibsovo and Idhifa. Even with more conservative estimates, he believes Tibsovo alone is worth $35 per share and Idhifa royalties from Celgene (CELG) are worth $4, giving the stock a one-year "floor valuation" of $39 per share. Meanwhile, feedback from doctors highlights a moderate but "real" commercial opportunity in PKD for Mitapivat, said Schmidt, who set a $55 price target on Agios shares.
11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded to Neutral at Baird
As reported previously, Baird analyst Brian Skorney downgraded Celgene to Neutral from Outperform. The analyst cited its recent upward move and doesn't see any reason for holding the shares ahead of ASH where any hair out the TRANSCEND data could put the entire CVR at risk. Skorney maintained his $101 price target on Celgene shares.
11/01/19
BARD
11/01/19
DOWNGRADE
Target $101
BARD
Neutral
Celgene downgraded d to Neutral from Outperform at Baird
Baird analyst Brian Skorney downgraded d to Neutral from Outperform with a $101 price target.
11/01/19
STPT
11/01/19
DOWNGRADE
STPT
Hold
Celgene downgraded to Hold from Buy at Standpoint Research
Standpoint Research analyst Ronnie Moas downgraded Celgene to Hold from Buy.
DISCK Discovery Inc.
$28.04

0.12 (0.43%)

TODAY'S FREE FLY STORIES

06:50
12/11/19
12/11
06:50
12/11/19
06:50
General news
FX Update: The dollar has seen ranges of no more than 20 pips »

FX Update: The dollar has…

UNH

UnitedHealth

$279.50

1.94 (0.70%)

06:49
12/11/19
12/11
06:49
12/11/19
06:49
Recommendations
UnitedHealth analyst commentary  »

UnitedHealth price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LLY

Eli Lilly

$120.64

0.34 (0.28%)

06:47
12/11/19
12/11
06:47
12/11/19
06:47
Hot Stocks
Eli Lilly opens LIBRETTO-431 clinical trial for selpercatinib »

Eli Lilly announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 30

    Jan

HUM

Humana

$344.57

2.27 (0.66%)

06:47
12/11/19
12/11
06:47
12/11/19
06:47
Recommendations
Humana analyst commentary  »

Humana price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LAZ

Lazard

$37.78

-0.34 (-0.89%)

06:46
12/11/19
12/11
06:46
12/11/19
06:46
Hot Stocks
Lazard reports preliminary AUM approximately $236.7B as of November 30 »

The month's AUM…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

VEEV

Veeva

$142.87

-0.69 (-0.48%)

06:46
12/11/19
12/11
06:46
12/11/19
06:46
Conference/Events
Veeva management to meet with William Blair »

Dinner Meeting with CFO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ROK

Rockwell Automation

$199.78

0.89 (0.45%)

06:46
12/11/19
12/11
06:46
12/11/19
06:46
Downgrade
Rockwell Automation rating change  »

Rockwell Automation…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JKHY

Jack Henry

$148.73

-0.17 (-0.11%)

06:46
12/11/19
12/11
06:46
12/11/19
06:46
Downgrade
Jack Henry rating change  »

Jack Henry downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WDR

Waddell & Reed

$16.41

-0.2 (-1.20%)

06:45
12/11/19
12/11
06:45
12/11/19
06:45
Hot Stocks
Waddell & Reed reports preliminary AUM $69.4B as of November 30 »

Compared to $68.9B on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

06:45
12/11/19
12/11
06:45
12/11/19
06:45
General news
Breaking General news story  »

Week of 12/6 MBA Mortgage…

06:45
12/11/19
12/11
06:45
12/11/19
06:45
General news
Breaking General news story  »

Week of 12/6 MBA Mortgage…

AZO

AutoZone

$1,250.39

79.085 (6.75%)

06:44
12/11/19
12/11
06:44
12/11/19
06:44
Recommendations
AutoZone analyst commentary  »

AutoZone price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 18

    Dec

ZEN

Zendesk

$73.94

-1.155 (-1.54%)

06:44
12/11/19
12/11
06:44
12/11/19
06:44
Conference/Events
Zendesk management to meet with William Blair »

Group Luncheon Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

HLFFF

HelloFresh

$0.00

(0.00%)

06:44
12/11/19
12/11
06:44
12/11/19
06:44
Downgrade
HelloFresh rating change  »

HelloFresh downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CUB

Cubic

$63.59

-0.93 (-1.44%)

06:42
12/11/19
12/11
06:42
12/11/19
06:42
Conference/Events
Cubic management to meet with William Blair »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

DDRLF

Maersk Drilling

$0.00

(0.00%)

06:42
12/11/19
12/11
06:42
12/11/19
06:42
Initiation
Maersk Drilling initiated  »

Maersk Drilling initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SVMK

SurveyMonkey

$17.09

-0.25 (-1.44%)

06:40
12/11/19
12/11
06:40
12/11/19
06:40
Conference/Events
SurveyMonkey management to meet with Stephens »

Group Luncheon Meeting…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

SAPMY

Saipem

$0.00

(0.00%)

06:39
12/11/19
12/11
06:39
12/11/19
06:39
Downgrade
Saipem rating change  »

Saipem downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SUBCY

Subsea 7

$0.00

(0.00%)

06:38
12/11/19
12/11
06:38
12/11/19
06:38
Upgrade
Subsea 7 rating change  »

Subsea 7 upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CGC

Canopy Growth

$20.09

-1.17 (-5.50%)

06:37
12/11/19
12/11
06:37
12/11/19
06:37
Conference/Events
Canopy Growth management to meet with Cantor Fitzgerald »

Cantor Analyst Pablo…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

TFX

Teleflex

$353.75

-3.65 (-1.02%)

06:35
12/11/19
12/11
06:35
12/11/19
06:35
Conference/Events
Teleflex management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

ACM

Aecom

$42.69

0.32 (0.76%)

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Recommendations
Aecom analyst commentary  »

Citi continues to like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACM

Aecom

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Recommendations
Aecom analyst commentary  »

Citi continues to like…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STX

Seagate

$57.61

0.49 (0.86%)

06:33
12/11/19
12/11
06:33
12/11/19
06:33
Conference/Events
Seagate management to meet with Loop Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

  • 07

    Jan

SONO

Sonos

$13.50

-0.12 (-0.88%)

06:32
12/11/19
12/11
06:32
12/11/19
06:32
Conference/Events
Sonos management to meet with DA Davidson »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 11

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.